A Phase I-II Study of Live Attenuated Varicella-zoster Virus Vaccine to Boost Immunity in Human Immunodeficiency Virus-infected Children with Previous Varicella

Overview

Journal Pediatr Infect Dis J

Specialty Pediatrics

Date 2009 Jun 30

PMID 19561431

Citations 10

Authors

Anne A Gershon

Myron J Levin

Adriana Weinberg

Lin-Yee Song

Philip S LaRussa

Sharon P Steinberg

Patterson Bartlett

Affiliations

Soon will be listed here.

Abstract

Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.

Citing Articles

Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.

Carta V, Mangeri L, Tiecco G, Foca E, Quiros-Roldan E, De Francesco M Hum Vaccin Immunother. 2024; 20(1):2341456.

PMID: 38650460 PMC: 11042063. DOI: 10.1080/21645515.2024.2341456.

Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.

Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P PLoS One. 2016; 11(8):e0157385.

PMID: 27490698 PMC: 4974007. DOI: 10.1371/journal.pone.0157385.

A literature review on the patients with autoimmune diseases following vaccination against infections.

Liang Y, Meng F, Pan H, Ye D Hum Vaccin Immunother. 2015; 11(9):2274-80.

PMID: 25875802 PMC: 4635701. DOI: 10.1080/21645515.2015.1009337.

Successes and challenges in varicella vaccine.

Papaloukas O, Giannouli G, Papaevangelou V Ther Adv Vaccines. 2014; 2(2):39-55.

PMID: 24757524 PMC: 3991154. DOI: 10.1177/2051013613515621.

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Langan S, Smeeth L, Margolis D, Thomas S PLoS Med. 2013; 10(4):e1001420.

PMID: 23585738 PMC: 3621740. DOI: 10.1371/journal.pmed.1001420.

References

Hayward A, Zerbe G, Levin M . Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods. 1994; 170(1):27-36. DOI: 10.1016/0022-1759(94)90242-9. View

Levin M, Gershon A, Weinberg A, Song L, Fentin T, Nowak B . Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006; 194(2):247-55. DOI: 10.1086/505149. View

Michalik D, Steinberg S, LaRussa P, Edwards K, Wright P, Arvin A . Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008; 197(7):944-9. PMC: 2657090. DOI: 10.1086/529043. View

Smith J, Levin M, Vessey R, Chan I, Hayward A, Liu X . Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J Med Virol. 2003; 70 Suppl 1:S38-41. DOI: 10.1002/jmv.10318. View

Gershon A, Mervish N, LaRussa P, Steinberg S, Lo S, Hodes D . Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis. 1997; 176(6):1496-500. DOI: 10.1086/514147. View

Levin M, Murray M, Rotbart H, Zerbe G, White C, Hayward A . Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992; 166(2):253-9. DOI: 10.1093/infdis/166.2.253. View

Wood S, Shah S, Steenhoff A, Rutstein R . Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics. 2007; 121(1):e150-6. DOI: 10.1542/peds.2007-0564. View

Levin M, Gershon A, Weinberg A, Blanchard S, Nowak B, Palumbo P . Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001; 139(2):305-10. DOI: 10.1067/mpd.2001.115972. View

Bekker V, Westerlaken G, Scherpbier H, Alders S, Zaaijer H, van Baarle D . Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS. 2006; 20(18):2321-9. DOI: 10.1097/QAD.0b013e3280113f29. View

10.

von Seidlein L, Gillette S, Bryson Y, Frederick T, Mascola L, Church J . Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr. 1996; 128(1):52-7. DOI: 10.1016/s0022-3476(96)70427-4. View

11.

Levin M, Oxman M, Zhang J, Johnson G, Stanley H, Hayward A . Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008; 197(6):825-35. PMC: 4014857. DOI: 10.1086/528696. View

12.

Levin M, Anderson J, Seage 3rd G, Williams P . Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009; 50(2):182-91. PMC: 2748317. DOI: 10.1097/QAI.0b013e31819550a4. View

13.

Derryck A, LaRussa P, Steinberg S, Capasso M, Pitt J, Gershon A . Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J. 1998; 17(10):931-3. DOI: 10.1097/00006454-199810000-00023. View

14.

Oxman M, Levin M, Johnson G, Schmader K, Straus S, Gelb L . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352(22):2271-84. DOI: 10.1056/NEJMoa051016. View

15.

Weinberg A, Wiznia A, LaFleur B, Shah S, Levin M . Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2004; 190(2):267-70. DOI: 10.1086/422011. View

16.

Williams V, Gershon A, Brunell P . Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis. 1974; 130(6):669-72. DOI: 10.1093/infdis/130.6.669. View

17.

Levin M, Smith J, Kaufhold R, Barber D, Hayward A, Chan C . Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003; 188(9):1336-44. DOI: 10.1086/379048. View